In adults with T2D and ASCVD, tirzepatide was noninferior to dulaglutide for a composite CV outcome at a median 4 y

Ann Intern Med. 2026 May;179(5):JC53. doi: 10.7326/ANNALS-26-00991-JC. Epub 2026 May 5.

Abstract

GIM/FP/GP:[Formula: see text] Cardiology:[Formula: see text] Endocrinology:[Formula: see text].

MeSH terms

  • Cardiovascular Diseases* / prevention & control
  • Diabetes Mellitus, Type 2* / complications
  • Diabetes Mellitus, Type 2* / drug therapy
  • Glucagon-Like Peptides* / adverse effects
  • Glucagon-Like Peptides* / analogs & derivatives
  • Glucagon-Like Peptides* / therapeutic use
  • Humans
  • Hypoglycemic Agents* / adverse effects
  • Hypoglycemic Agents* / therapeutic use
  • Immunoglobulin Fc Fragments* / adverse effects
  • Immunoglobulin Fc Fragments* / therapeutic use
  • Recombinant Fusion Proteins* / adverse effects
  • Recombinant Fusion Proteins* / therapeutic use
  • Tirzepatide

Substances

  • Tirzepatide
  • Recombinant Fusion Proteins
  • dulaglutide
  • Immunoglobulin Fc Fragments
  • Glucagon-Like Peptides
  • Hypoglycemic Agents